$IVDA
Iveda Solutions, Inc. Stock $ivda

$ivda Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022399 Filed on August 12, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q4
Revenue	$1.467M	$651.4K	$613.1K
YoY Change	256.59%	16.18%	-58.69%
Cost Of Revenue	$1.113M	$462.5K	$303.7K
YoY Change	712.89%	8.2%	-69.37%
Gross Profit	$354.4K	$188.9K	$309.4K
YoY Change	29.09%	41.78%	-37.2%
Gross Profit Margin	24.16%	29.0%	50.47%
Selling, General & Admin	$1.032M	$1.247M	$1.516M
YoY Change	47.66%	60.78%	-11.96%
% of Gross Profit	291.09%	660.2%	489.81%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$4.180K	$4.300K	-$2.130K
YoY Change	-44.12%	-55.53%	-113.57%
% of Gross Profit	1.18%	2.28%	-0.69%
Operating Expenses	$1.032M	$1.247M	$1.516M
YoY Change	47.66%	60.78%	-11.96%
Operating Profit	-$677.3K	-$1.058M	-$1.206M
YoY Change	59.68%	64.72%	-1.84%
Interest Expense	$15.18K	$13.48K	-$16.83K
YoY Change	-151.83%	-70.17%	-95.77%
% of Operating Profit
Other Income/Expense, Net	$10.59K	-$6.790K	$70.00
YoY Change		-84.96%	-99.71%
Pretax Income	-$666.7K	-$1.065M	-$1.223M
YoY Change	47.03%	54.89%	-23.68%
Income Tax	-$60.00	-$78.00	$0.00
% Of Pretax Income
Net Earnings	-$666.6K	-$1.065M	-$1.223M
YoY Change	47.02%	54.88%	-23.68%
Net Earnings / Revenue	-45.44%	-163.48%	-199.46%
Basic Earnings Per Share	-$0.04	-$0.09
Diluted Earnings Per Share	-$57.09K	-$91.19K	-$126.5K
COMMON SHARES
Basic Shares Outstanding	11.68M shares	11.68M shares
Diluted Shares Outstanding	14.97M shares	11.68M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.56M	$6.197M	$1.385M
YoY Change	757.19%	421.29%
Cash & Equivalents	$10.56M	$6.197M	$1.385M
Short-Term Investments
Other Short-Term Assets	$107.7K	$244.5K	$310.7K
YoY Change	-84.03%	-66.42%
Inventory	$718.5K	$630.4K	$344.7K
Prepaid Expenses
Receivables	$636.4K	$122.6K	$492.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.14M	$7.328M	$2.676M
YoY Change	397.51%	205.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.70K	$31.19K	$38.19K
YoY Change	-0.69%	-52.0%
Goodwill
YoY Change
Intangibles	$0.00	$0.00	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$235.9K	$232.3K	$273.4K
YoY Change	36.55%	34.96%
Total Long-Term Assets	$264.6K	$263.5K	$311.6K
YoY Change	31.22%	11.13%
TOTAL ASSETS
Total Short-Term Assets	$12.14M	$7.328M	$2.676M
Total Long-Term Assets	$264.6K	$263.5K	$311.6K
Total Assets	$12.41M	$7.592M	$2.988M
YoY Change	369.56%	187.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$790.2K	$375.8K	$62.89K
YoY Change	-76.44%	-89.17%
Accrued Expenses	$1.323M	$1.596M	$2.835M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$1.245M	$218.3K	$50.00K
YoY Change	119.36%	-78.96%
Long-Term Debt Due	$104.8K	$112.2K	$120.3K
YoY Change	118.63%
Total Short-Term Liabilities	$3.792M	$2.761M	$3.426M
YoY Change	-11.15%	-42.56%
LONG-TERM LIABILITIES
Long-Term Debt	$216.6K	$259.9K	$338.8K
YoY Change	218.92%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$216.6K	$259.9K	$338.8K
YoY Change	218.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.792M	$2.761M	$3.426M
Total Long-Term Liabilities	$216.6K	$259.9K	$338.8K
Total Liabilities	$4.009M	$3.021M	$3.765M
YoY Change	-7.55%	-37.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$43.76M	-$43.09M	-$41.36M
YoY Change	1.77%	0.22%
Common Stock	$150.00	$117.00	$97.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.398M	$4.571M	-$777.3K
YoY Change
Total Liabilities & Shareholders Equity	$12.41M	$7.592M	$2.988M
YoY Change	369.56%	187.74%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	-$666.6K	-$1.065M	-$1.223M
YoY Change	47.02%	54.88%	-23.68%
Depreciation, Depletion And Amortization	$4.180K	$4.300K	-$2.130K
YoY Change	-44.12%	-55.53%	-113.57%
Cash From Operating Activities	-$1.113M	-$1.413M	-$792.4K
YoY Change	172.78%	83.11%	1457.74%
INVESTING ACTIVITIES
Capital Expenditures	-$3.220K	$2.740K	-$7.160K
YoY Change	-111.25%	-105.96%	-153.47%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.220K	$2.740K	-$7.160K
YoY Change	-111.25%	-105.96%	-153.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.535M	6.907M	964.4K
YoY Change	1223.6%	296.94%	2221.08%
NET CHANGE
Cash From Operating Activities	-1.113M	-1.413M	-792.4K
Cash From Investing Activities	-3.220K	2.740K	-7.160K
Cash From Financing Activities	5.535M	6.907M	964.4K
Net Change In Cash	4.419M	5.497M	164.8K
YoY Change	11308.75%	495.88%	3949.88%
FREE CASH FLOW
Cash From Operating Activities	-$1.113M	-$1.413M	-$792.4K
Capital Expenditures	-$3.220K	$2.740K	-$7.160K
Free Cash Flow	-$1.110M	-$1.416M	-$785.3K
YoY Change	154.17%	95.08%	1122.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts		usd
	IVDA	Stock Issued During Period Value Common Stock Issued For Conversion Error StockIssuedDuringPeriodValueCommonStockIssuedForConversionError		usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001397183
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	IVEDA SOLUTIONS, INC.
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	IVDA	Common Stock Issued For Consulting Agreements Related To Cost Of Capital CommonStockIssuedForConsultingAgreementsRelatedToCostOfCapital		usd
	IVDA	Debenture Accrued Interest Converted To Common Stock DebentureAccruedInterestConvertedToCommonStock		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	IVDA	Rent Accounts Payable To Related Party Converted To Common Stock RentAccountsPayableToRelatedPartyConvertedToCommonStock		usd
	IVDA	Accrued Dividends Converted To Common Stock AccruedDividendsConvertedToCommonStock		usd
CY2022Q2	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent		usd
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent		usd
CY2021Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards		usd
CY2020Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41345
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2222203
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1744 S Val Vista
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 213
	dei	Entity Address City Or Town EntityAddressCityOrTown	Mesa
	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85204
	dei	City Area Code CityAreaCode	(480)
	dei	Local Phone Number LocalPhoneNumber	307-8700
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11677265	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6197455	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1385275	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	133093	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	142688	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	122602	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	492752	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	630416	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	344654	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	244548	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	310657	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	7328114	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2676026	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	218282	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	50000	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	112188	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	120284	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2760852	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3426110	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31194	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38189	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	232320	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	273419	usd
CY2022Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	232320	usd
CY2021Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	273419	usd
CY2022Q2	us-gaap	Assets Assets	7591628	usd
CY2021Q4	us-gaap	Assets Assets	2987634	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2130382	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2955826	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	300000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	300000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	259903	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	338803	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	12500000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	12500000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	37500000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	37500000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11677265	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11677265	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9668369	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9668369	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	117	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	97	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47862427	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40727518	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-198572	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-143493	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43093099	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41361401	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	4570873	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-777279	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7591628	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2987634	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	651412	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	560692	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	882269	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	893272	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	462516	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	427457	usd
	us-gaap	Cost Of Revenue CostOfRevenue	552826	usd
	us-gaap	Cost Of Revenue CostOfRevenue	645008	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	188896	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	133235	usd
	us-gaap	Gross Profit GrossProfit	329443	usd
	us-gaap	Gross Profit GrossProfit	248264	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1247084	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	775657	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2039247	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1343306	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1247084	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	775657	usd
	us-gaap	Operating Expenses OperatingExpenses	2039247	usd
	us-gaap	Operating Expenses OperatingExpenses	1343306	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1058188	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-642422	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1709804	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1095042	usd
CY2022Q2	IVDA	Miscellaneous Income Expense MiscellaneousIncomeExpense	-4	usd
CY2021Q2	IVDA	Miscellaneous Income Expense MiscellaneousIncomeExpense	-67	usd
	IVDA	Miscellaneous Income Expense MiscellaneousIncomeExpense	167	usd
	IVDA	Miscellaneous Income Expense MiscellaneousIncomeExpense	-67	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	6693	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	97	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7309	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	135	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	13479	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	45191	usd
	us-gaap	Interest Expense InterestExpense	26312	usd
	us-gaap	Interest Expense InterestExpense	227323	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6790	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-45161	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18836	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-227255	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1064978	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-687583	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1728640	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1322297	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-78	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3058	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1064900	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-687583	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1731698	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1322297	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11677265	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8999062	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10676956	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8417157	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-3706568	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2662000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-2091101	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	801908	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	99789	usd
CY2021	IVDA	Stock Issued During Period Value Common Stock For Costs Of Financing StockIssuedDuringPeriodValueCommonStockForCostsOfFinancing	1932736	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	148480	usd
CY2021	IVDA	Adjustments To Additional Paid In Capital Warrants For Interest Expense AdjustmentsToAdditionalPaidInCapitalWarrantsForInterestExpense	69729	usd
CY2021	IVDA	Adjustments To Additional Paid In Capital Convertible Debenture Valuation AdjustmentsToAdditionalPaidInCapitalConvertibleDebentureValuation	69729	usd
CY2021	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	23750	usd
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	432176	usd
CY2021	IVDA	Additional Paid In Capital Accumulated Deficit Dividends Preferred Stock AdditionalPaidInCapitalAccumulatedDeficitDividendsPreferredStock	-40301	usd
CY2021	IVDA	Stock Issued During Period Value Conversion Of Convertible Securities Interest To Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesInterestToCommonStock	1294580	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	514697	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2998644	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	9761	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-777279	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-1163918	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	93900	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	167900	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8011250	usd
	IVDA	Adjustments To Additional Paid In Capital Warrants Sold In Over Allotment AdjustmentsToAdditionalPaidInCapitalWarrantsSoldInOverAllotment	2797	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1731698	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-55079	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	4570873	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1731698	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1322297	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8959	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9666	usd
	IVDA	Interest Value Of Convertible Debt Issued InterestValueOfConvertibleDebtIssued	69729	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	93900	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	88000	usd
	IVDA	Issuance Of Stock Issued For Services IssuanceOfStockIssuedForServices	167900	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	71793	usd
	IVDA	Common Stock Warrants Issued For Interest Value CommonStockWarrantsIssuedForInterestValue	69729	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-370150	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1807	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	285762	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	37426	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	22220	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	274265	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-41295	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-60476	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-825640	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	491169	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2183116	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-771619	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1964	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45959	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1964	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45959	usd
	IVDA	Proceeds From Restricted Cash ProceedsFromRestrictedCash	-9596	usd
	IVDA	Proceeds From Restricted Cash ProceedsFromRestrictedCash	166721	usd
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	160186	usd
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	481450	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-82711	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-78900	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6961457	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1508000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7052339	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1740018	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-55079	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16906	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4812180	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	939346	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1385275	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	249521	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6197455	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1188867	usd
	us-gaap	Interest Paid Net InterestPaidNet	1013	usd
	us-gaap	Interest Paid Net InterestPaidNet	330	usd
	IVDA	Common Stock Issued For Consulting Agreements Related To Cost Of Capital CommonStockIssuedForConsultingAgreementsRelatedToCostOfCapital	1895000	usd
	IVDA	Debenture Accrued Interest Converted To Common Stock DebentureAccruedInterestConvertedToCommonStock	125376	usd
	us-gaap	Stock Issued1 StockIssued1	439750	usd
	IVDA	Rent Accounts Payable To Related Party Converted To Common Stock RentAccountsPayableToRelatedPartyConvertedToCommonStock	55789	usd
	IVDA	Accrued Dividends Converted To Common Stock AccruedDividendsConvertedToCommonStock	455926	usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.96
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	62500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.72
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43000000	usd
CY2022Q2	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	543754	shares
CY2021Q2	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2022Q2	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	872259	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_za6m0gM1bMhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_869_zQ5bSSZt5Xug">Use of Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	158750	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.28
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	137963	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.44
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	44375	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zmPqZU5jFFlf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_862_zIiAsBWuWcDf">Concentrations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash and cash equivalents and trade accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially all cash is deposited in two financial institutions, one in the United States and one in Taiwan. At times, amounts on deposit in the United States may be in excess of the FDIC insurance limit. Deposits in Taiwan financial institutions are insured by CDIC (Central Deposit Insurance Corporation) with maximum coverage of NTD <span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_pn6n6_uNTD_c20220630_zzYIDA5aLAA9" title="FDIC insurance limit">3</span> million. At times, amounts on deposit in Taiwan may be in excess of the CDIC Insurance limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivables are unsecured, and we are at risk to the extent such amount becomes uncollectible. We perform periodic credit evaluations of our customers’ financial condition and generally do not require collateral. One customer (Chunghwa Telecom) represented approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_zcZXGHkgFbqi" title="Percentage of concentration risk">95</span>% of total accounts receivable of $<span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_zQpWaW8J5d3" title="Account receivable">492,752</span> as of December 31, 2021. This customer is a longtime customer, and we do not expect any problem with the collectability of these accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We had revenue from one customer with greater than <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--RangeAxis__srt--MinimumMember_zTodUCgqyDqc">10</span>% of total revenues during the six months ended June 30, 2022 and two customers for the year ended December 31, 2021 that represented approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zT6h34N4LOFd" title="Concentration risk, percentage">53</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zCKDtTarr9A9" title="Concentration risk, percentage">55</span>% of total revenues, respectively. We had $<span id="xdx_90B_eus-gaap--Revenues_pp0p0_c20220101__20220630__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_zq3NEkVVFwuj" title="Revenues">527,256</span> revenues (<span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_ztL7DsLj46Qc" title="Concentration risk, percentage">60</span>%) from Chunghwa Telecom of total revenues of $<span id="xdx_901_eus-gaap--Revenues_pp0p0_c20220101__20220630_zHiOQeS1n0mb" title="Revenues">882,269</span> for the six months ended June 30, 2022. We had $<span id="xdx_90E_eus-gaap--Revenues_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_zhsUciCSPl2k" title="Revenues">786,686</span> revenues (<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_z5woeYv5FTMf" title="Concentration risk, percentage">41</span>%) from Chunghwa Telecom and $<span id="xdx_901_eus-gaap--Revenues_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--TaiwanStockExchangeCorporationMember_zhXclxxFlNv6" title="Revenues">260,946</span> revenues (<span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--TaiwanStockExchangeCorporationMember_zmLZ6v2Yr2Ua" title="Concentration risk, percentage">14</span>%) from Taiwan Stock Exchange Corporation of total revenues of $<span id="xdx_907_eus-gaap--Revenues_pp0p0_c20210101__20211231_z4qaa79auUyi" title="Revenues">1,917,848</span> for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No other customers represented greater than <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__us-gaap--RangeAxis__us-gaap--MinimumMember_zsXFqhvnQbX1" title="Percentage of concentration risk"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__us-gaap--RangeAxis__us-gaap--MinimumMember_zTXos9sTnMgc" title="Percentage of concentration risk">10</span></span>% of total revenues in the six months ended June 30, 2022 and year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	3000000
	us-gaap	Revenues Revenues	882269	usd
CY2021	us-gaap	Revenues Revenues	1917848	usd
CY2022Q2	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	3.04
CY2021Q2	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	543754	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.96
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	893438	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.80
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	952025	shares
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2021Q2	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	3.04
	us-gaap	Depreciation Depreciation	8959	usd
CY2021	us-gaap	Depreciation Depreciation	15016	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	375774	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	62889	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1595660	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2834726	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	158948	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	58211	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2130382	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2955826	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.76
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	891563	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.80
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_znBr4C8sR3h2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86A_ziHMBwXCtOY6">Reclassification</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in 2021 have been reclassified to conform to the 2022 presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	300000	usd
CY2021Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	300000	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	300000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	300000	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	218282	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	50000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	952025	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.00
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	872259	shares
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	112188	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	120284	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	259903	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	338803	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	12500000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	37500000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of the stockholders of our company
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4500	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	952025	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.76
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	842650	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.24
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	141875	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	312500	shares
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	0.32
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	16.24
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	893438	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y2M12D
CY2022Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6.80
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	891563	shares
CY2022Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	6.80
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0100	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0018	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	543754	shares
CY2021Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	695439	shares
CY2020Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	509732	shares
	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice	2.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	123732	shares
	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice	2.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	78102	shares
	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice	2.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	103125	shares
	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeited Cancelled Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeitedCancelledWeightedAverageExercisePrice	2.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	275416	shares
	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeited Cancelled Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeitedCancelledWeightedAverageExercisePrice	2.88
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	872259	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y6M
CY2022Q2	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2022Q2	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	872259	shares
CY2022Q2	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	3.04
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	10800000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	9800000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10800000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9800000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1000000	usd
CY2021	IVDA	Year Of Expiration YearOfExpiration	2041
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	590000	usd
CY2020	IVDA	Year Of Expiration YearOfExpiration	2040
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	260000	usd
CY2019	IVDA	Year Of Expiration YearOfExpiration	2039
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	160000	usd
CY2018	IVDA	Year Of Expiration YearOfExpiration	2038
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	140000	usd
CY2017	IVDA	Year Of Expiration YearOfExpiration	2037
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1640000	usd
CY2016	IVDA	Year Of Expiration YearOfExpiration	2036
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3400000	usd
CY2015	IVDA	Year Of Expiration YearOfExpiration	2035
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5230000	usd
CY2014	IVDA	Year Of Expiration YearOfExpiration	2034
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5600000	usd
CY2013	IVDA	Year Of Expiration YearOfExpiration	2033
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2850000	usd
CY2012	IVDA	Year Of Expiration YearOfExpiration	2032
CY2011Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2427000	usd
CY2011	IVDA	Year Of Expiration YearOfExpiration	2031
CY2010Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1799000	usd
CY2010	IVDA	Year Of Expiration YearOfExpiration	2030
CY2009Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1750000	usd
CY2009	IVDA	Year Of Expiration YearOfExpiration	2029
CY2008Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1308000	usd
CY2008	IVDA	Year Of Expiration YearOfExpiration	2028
CY2007Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	429000	usd
CY2007	IVDA	Year Of Expiration YearOfExpiration	2027
CY2006Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	476000	usd
CY2006	IVDA	Year Of Expiration YearOfExpiration	2026
CY2005Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	414000	usd
CY2005	IVDA	Year Of Expiration YearOfExpiration	2025
	IVDA	Taiwan Corporate Tax Rate TaiwanCorporateTaxRate	Sole-Vision Technologies, Inc. is a subsidiary of the Company which is operating in Taiwan as a profit-seeking enterprise. Its applicable corporate income tax rate is 17%. In addition, Taiwan’s corporate tax system allows the government to levy a 10% profit retention tax on undistributed earnings for the prior year. This tax will not be provided if the company distributed the earnings before the ended of the fiscal year
	us-gaap	Net Income Loss NetIncomeLoss	-1731698	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1322297	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10676647	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8417157	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16

Files In Submission

Name	View Source	Status
0001493152-22-022399-index-headers.html	Edgar Link	pending
0001493152-22-022399-index.html	Edgar Link	pending
0001493152-22-022399.txt	Edgar Link	pending
0001493152-22-022399-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
ivda-20220630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
ivda-20220630_lab.xml	Edgar Link	unprocessable
ivda-20220630_def.xml	Edgar Link	unprocessable
ivda-20220630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ivda-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IVDA
Iveda Solutions, Inc. Stock $ivda

2022 Q3 Form 10-Q Financial Statement

#000149315222022399 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IVDA Iveda Solutions, Inc. Stock $ivda

2022 Q3 Form 10-Q Financial Statement

#000149315222022399 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IVDA
Iveda Solutions, Inc. Stock $ivda